These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 32535897)

  • 1. Understanding the Effect of Hydroxypropyl-β-Cyclodextrin on Fenebrutinib Absorption in an Itraconazole-Fenebrutinib Drug-Drug Interaction Study.
    Durk MR; Jones NS; Liu J; Nagapudi K; Mao C; Plise EG; Wong S; Chen JZ; Chen Y; Chinn LW; Chiang PC
    Clin Pharmacol Ther; 2020 Dec; 108(6):1224-1232. PubMed ID: 32535897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physiologically-Based Pharmacokinetic Model-Informed Drug Development for Fenebrutinib: Understanding Complex Drug-Drug Interactions.
    Chen Y; Ma F; Jones NS; Yoshida K; Chiang PC; Durk MR; Wright MR; Jin JY; Chinn LW
    CPT Pharmacometrics Syst Pharmacol; 2020 Jun; 9(6):332-341. PubMed ID: 32383787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Absence of Pharmacokinetic Interactions between the Bruton's Tyrosine Kinase Inhibitor Fenebrutinib and Methotrexate.
    Jones NS; Winter H; Katsumoto TR; Florero M; Murray E; Walker H; Singh N; Chinn LW
    J Pharmacol Exp Ther; 2019 Oct; 371(1):202-207. PubMed ID: 31371481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Linking the concentrations of itraconazole and 2-hydroxypropyl-β-cyclodextrin in human intestinal fluids after oral intake of Sporanox
    Berben P; Stappaerts J; Vink MJA; Domínguez-Vega E; Somsen GW; Brouwers J; Augustijns P
    Eur J Pharm Biopharm; 2018 Nov; 132():231-236. PubMed ID: 29959034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gastrointestinal behavior of itraconazole in humans - Part 2: The effect of intraluminal dilution on the performance of a cyclodextrin-based solution.
    Berben P; Mols R; Brouwers J; Tack J; Augustijns P
    Int J Pharm; 2017 Jun; 526(1-2):235-243. PubMed ID: 28450167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of hydroxypropyl-beta-cyclodextrin on efficacy of oral itraconazole in disseminated murine cryptococcosis.
    Hostetler JS; Hanson LH; Stevens DA
    J Antimicrob Chemother; 1993 Sep; 32(3):459-63. PubMed ID: 8262868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intestinal Permeability of β-Lapachone and Its Cyclodextrin Complexes and Physical Mixtures.
    Mangas-Sanjuan V; Gutiérrez-Nieto J; Echezarreta-López M; González-Álvarez I; González-Álvarez M; Casabó VG; Bermejo M; Landin M
    Eur J Drug Metab Pharmacokinet; 2016 Dec; 41(6):795-806. PubMed ID: 26602766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of grapefruit juice on the systemic availability of itraconazole oral solution in healthy adult volunteers.
    Gubbins PO; McConnell SA; Gurley BJ; Fincher TK; Franks AM; Williams DK; Penzak SR; Saccente M
    Pharmacotherapy; 2004 Apr; 24(4):460-7. PubMed ID: 15098799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy, Safety, and Pharmacodynamic Effects of the Bruton's Tyrosine Kinase Inhibitor Fenebrutinib (GDC-0853) in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double-Blind, Placebo-Controlled Trial.
    Isenberg D; Furie R; Jones NS; Guibord P; Galanter J; Lee C; McGregor A; Toth B; Rae J; Hwang O; Desai R; Lokku A; Ramamoorthi N; Hackney JA; Miranda P; de Souza VA; Jaller-Raad JJ; Maura Fernandes A; Garcia Salinas R; Chinn LW; Townsend MJ; Morimoto AM; Tuckwell K
    Arthritis Rheumatol; 2021 Oct; 73(10):1835-1846. PubMed ID: 34042314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of itraconazole/2-hydroxypropyl-beta-cyclodextrin inclusion complex in aqueous propylene glycol solution.
    Miyake K; Irie T; Arima H; Hirayama F; Uekama K; Hirano M; Okamaoto Y
    Int J Pharm; 1999 Mar; 179(2):237-45. PubMed ID: 10053216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro-in vivo correlation in the effect of cyclodextrin on oral absorption of poorly soluble drugs.
    Aihara R; Messerschmid R; Mizoguchi M; Wada K; Minami K; Higashino H; Takagi T; Kataoka M; Yamashita S
    Int J Pharm; 2021 May; 600():120494. PubMed ID: 33744446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A pharmacokinetic study of intravenous itraconazole followed by oral administration of itraconazole capsules in patients with advanced human immunodeficiency virus infection.
    Zhou H; Goldman M; Wu J; Woestenborghs R; Hassell AE; Lee P; Baruch A; Pesco-Koplowitz L; Borum J; Wheat LJ
    J Clin Pharmacol; 1998 Jul; 38(7):593-602. PubMed ID: 9702843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concentrations in plasma and safety of 7 days of intravenous itraconazole followed by 2 weeks of oral itraconazole solution in patients in intensive care units.
    Vandewoude K; Vogelaers D; Decruyenaere J; Jaqmin P; De Beule K; Van Peer A; Woestenborghs R; Groen K; Colardyn F
    Antimicrob Agents Chemother; 1997 Dec; 41(12):2714-8. PubMed ID: 9420044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, Pharmacokinetics, and Pharmacodynamics in Healthy Volunteers Treated With GDC-0853, a Selective Reversible Bruton's Tyrosine Kinase Inhibitor.
    Herman AE; Chinn LW; Kotwal SG; Murray ER; Zhao R; Florero M; Lin A; Moein A; Wang R; Bremer M; Kokubu S; Serone AP; Hanze EL; Viberg A; Morimoto AM; Winter HR; Katsumoto TR
    Clin Pharmacol Ther; 2018 Jun; 103(6):1020-1028. PubMed ID: 29484638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improvement of solubility and oral bioavailability of rutin by complexation with 2-hydroxypropyl-beta-cyclodextrin.
    Miyake K; Arima H; Hirayama F; Yamamoto M; Horikawa T; Sumiyoshi H; Noda S; Uekama K
    Pharm Dev Technol; 2000; 5(3):399-407. PubMed ID: 10934740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced bioavailability of itraconazole in hydroxypropyl-beta-cyclodextrin solution versus capsules in healthy volunteers.
    Barone JA; Moskovitz BL; Guarnieri J; Hassell AE; Colaizzi JL; Bierman RH; Jessen L
    Antimicrob Agents Chemother; 1998 Jul; 42(7):1862-5. PubMed ID: 9661037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of intravenous itraconazole followed by itraconazole oral solution in patients with human immunodeficiency virus infection.
    Zhao Q; Zhou H; Pesco-Koplowitz L
    J Clin Pharmacol; 2001 Dec; 41(12):1319-28. PubMed ID: 11762559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An Investigation of Oral Exposure Variability and Formulation Strategy: A Case Study of PI3Kδ Inhibitor and Physiologically Based Pharmacokinetic Modeling in Beagle Dogs.
    Chiang PC; Pang J; Liu J; Salphati L
    J Pharm Sci; 2018 Jan; 107(1):466-475. PubMed ID: 28652157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complex DDI by Fenebrutinib and the Use of Transporter Endogenous Biomarkers to Elucidate the Mechanism of DDI.
    Jones NS; Yoshida K; Salphati L; Kenny JR; Durk MR; Chinn LW
    Clin Pharmacol Ther; 2020 Jan; 107(1):269-277. PubMed ID: 31376152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development.
    Crawford JJ; Johnson AR; Misner DL; Belmont LD; Castanedo G; Choy R; Coraggio M; Dong L; Eigenbrot C; Erickson R; Ghilardi N; Hau J; Katewa A; Kohli PB; Lee W; Lubach JW; McKenzie BS; Ortwine DF; Schutt L; Tay S; Wei B; Reif K; Liu L; Wong H; Young WB
    J Med Chem; 2018 Mar; 61(6):2227-2245. PubMed ID: 29457982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.